Literature DB >> 19160528

Does the renin-angiotensin system also regulate intra-ocular pressure?

Anu Vaajanen1, Satu Luhtala, Olli Oksala, Heikki Vapaatalo.   

Abstract

The renin-angiotensin-aldosterone system is known to play an essential role in controlling sodium balance and body fluid volumes, and thus blood pressure. In addition to the circulating system which regulates urgent cardiovascular responses, a tissue-localized renin-angiotensin system (RAS) regulates long-term changes in various organs. Many recognized RAS components have also been identified in the human eye. The highly vasoconstrictive angiotensin II (Ang II) is considered the key peptide in the circulatory RAS. However, the ultimate effect of RAS activation at tissue level is more complex, being based not only on the biological activity of Ang II but also on the activities of other products of angiotensinogen metabolism, often exerting opposite effects to Ang II action. In recent studies, orally administered angiotensin II type 1 receptor blockers and angiotensin-converting enzyme inhibitors lower intra-ocular pressure (IOP), likewise topical application of these compounds, the effect being more prominent in ocular hypertensive eyes. Based on previous findings and our own experimental data, it can strongly be suggested that the RAS not only regulates blood pressure but is also involved in the regulation of IOP.

Entities:  

Mesh:

Year:  2008        PMID: 19160528     DOI: 10.1080/07853890802043924

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  13 in total

Review 1.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

2.  1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates.

Authors:  Galina D Kutuzova; B'ann T Gabelt; Julie A Kiland; Elizabeth A Hennes-Beann; Paul L Kaufman; Hector F DeLuca
Journal:  Arch Biochem Biophys       Date:  2011-12-16       Impact factor: 4.013

3.  Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.

Authors:  Mervi Holappa; Heikki Vapaatalo; Anu Vaajanen
Journal:  Ann Med       Date:  2020-04-30       Impact factor: 4.709

Review 4.  Impact of arterial hypertension on the eye.

Authors:  Vasiliki Katsi; Maria Marketou; Charalambos Vlachopoulos; Dimitris Tousoulis; George Souretis; Nikolaos Papageorgiou; Christodoulos Stefanadis; Panos Vardas; Ioannis Kallikazaros
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

Review 5.  The microfibril hypothesis of glaucoma: implications for treatment of elevated intraocular pressure.

Authors:  John Kuchtey; Rachel W Kuchtey
Journal:  J Ocul Pharmacol Ther       Date:  2014-02-12       Impact factor: 2.671

6.  Novel ocular antihypertensive compounds in clinical trials.

Authors:  June Chen; Stephen A Runyan; Michael R Robinson
Journal:  Clin Ophthalmol       Date:  2011-05-20

7.  Angiotensin(1-7) and ACE2, "The Hot Spots" of Renin-Angiotensin System, Detected in the Human Aqueous Humor.

Authors:  Mervi Holappa; Jarkko Valjakka; Anu Vaajanen
Journal:  Open Ophthalmol J       Date:  2015-03-31

8.  The expression of Mas-receptor of the renin-angiotensin system in the human eye.

Authors:  A Vaajanen; G Kalesnykas; H Vapaatalo; H Uusitalo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-14       Impact factor: 3.117

9.  Expression and cellular localization of the Mas receptor in the adult and developing mouse retina.

Authors:  Tuhina Prasad; Amrisha Verma; Qiuhong Li
Journal:  Mol Vis       Date:  2014-10-17       Impact factor: 2.367

Review 10.  The effects of Ramadan fasting on the health and function of the eye.

Authors:  Mohammad Ali Javadi; Mahsan Assadi; Bahram Einollahi; Hossein Mohammad Rabei; Mehrdad Afarid; Majid Assadi
Journal:  J Res Med Sci       Date:  2014-08       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.